CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

Bibliographic Details
Main Authors:	Rimal Ilyas, Kristen McCullough, Talha Badar, Mrinal M. Patnaik, Hassan Alkhateeb, Abhishek Mangaonkar, Animesh Pardanani, Ayalew Tefferi, Naseema Gangat
Format:	Article
Language:	English
Published:	Nature Publishing Group 2023-02-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00800-2

Similar Items

CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report
by: Ruth M. Urbantat, et al.
Published: (2021-04-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
by: Ayalew Tefferi, et al.
Published: (2023-07-01)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
by: Naseema Gangat, et al.
Published: (2022-12-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2023-03-01)

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
by: Terra L. Lasho, et al.
Published: (2018-02-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-06-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
by: Naseema Gangat, et al.
Published: (2023-03-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
by: Maymona G. Abdelmagid, et al.
Published: (2023-02-01)

<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
by: Mrinal M. Patnaik, et al.
Published: (2019-06-01)

Sodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
by: Ali Alsugair, et al.
Published: (2025-01-01)

Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience
by: Naseema Gangat, et al.
Published: (2022-02-01)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-04-01)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
by: Naseema Gangat, et al.
Published: (2020-11-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
by: Nickolas Steinauer, et al.
Published: (2024-03-01)

Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2023-08-01)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
by: Mostafa Abdallah, et al.
Published: (2023-03-01)

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis
by: Animesh Pardanani, et al.
Published: (2011-01-01)

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
by: Ayalew Tefferi, et al.
Published: (2024-03-01)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
by: Naseema Gangat, et al.
Published: (2023-01-01)

CPX-351 in FLT3-mutated acute myeloid leukemia
by: Claire Andrews, et al.
Published: (2023-11-01)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
by: A. Kaifie, et al.
Published: (2016-03-01)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
by: Julian Baumeister, et al.
Published: (2021-12-01)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
by: Evandro D. Bezerra, et al.
Published: (2021-03-01)

UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN
by: Harrison, C, et al.
Published: (2019)

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
by: Saubia Fathima, et al.
Published: (2025-03-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
by: Ayalew Tefferi, et al.
Published: (2022-06-01)

Hypothetical atopic dermatitis-myeloproliferative neoplasm (AD-MPN) syndrome
by: Toshiaki eKawakami, et al.
Published: (2015-08-01)

Secondary acute leukemia evolving from myeloproliferative neoplasm (MPN)
by: Tariq Mughal
Published: (2020-10-01)

How we diagnose and treat WHO-defined systemic mastocytosis in adults
by: Ayalew Tefferi, et al.
Published: (2008-01-01)

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
by: I. Johnson, et al.
Published: (2022-06-01)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
by: Ahmad Ghorab, et al.
Published: (2022-06-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
by: Butt, N, et al.
Published: (2019)

P984: MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN)
by: I. C. Casetti, et al.
Published: (2022-06-01)

Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
by: Giuseppe Gaetano Loscocco, et al.
Published: (2024-07-01)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
by: Maymona G. Abdelmagid, et al.
Published: (2022-07-01)

Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine
by: Naseema Gangat, et al.
Published: (2023-11-01)

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
by: Mostafa Abdallah, et al.
Published: (2024-03-01)